.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,635,172

« Back to Dashboard

Summary for Patent: 5,635,172

Title: Sustained release comfort formulation for glaucoma therapy
Abstract:Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering of intraocular pressure.
Inventor(s): Jani; Rajni (Fort Worth, TX), Harris; Robert G. (Fort Worth, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:08/396,284
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;
Patent PDF download available with subscription

No matches for this query

International Patent Family for Patent: 5,635,172

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia1607495<disabled in preview>
Australia4575389<disabled in preview>
Australia621692<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc